Literature DB >> 16291439

Defining the outcomes of risk stratification studies of ED patients with chest pain: the marginal value of adding revascularization to the composite end point.

Esther H Chen1, Frank Sites, Frances S Shofer, Judd E Hollander.   

Abstract

OBJECTIVES: Cardiovascular risk stratification studies use various end points, sometimes including revascularization. We assessed whether adding revascularization to a strictly defined composite end point of death, acute myocardial infarction (AMI), and unstable angina (UA) impacts the likelihood of patients attaining the composite end point.
METHODS: We conducted a secondary analysis of a prospectively collected data set of emergency department patients who received an electrocardiogram for chest pain. Patients were followed daily; discharged patients had 30-day telephone follow-up. The main outcome was a 30-day composite end point of death, AMI, and UA compared with death, AMI, UA, and revascularization.
RESULTS: There were 4492 patients enrolled (mean age, 52 +/- 16 years; men, 41%; African American, 68%). One hundred seventy patients were revascularized (158 had AMI or UA). Overall, the incidence of death/AMI/UA was 20.1% (95% confidence interval, 18.9%-21.2%). With revascularization included, the incidence of the composite end point was 20.3% (95% confidence interval, 19.1%-21.5%).
CONCLUSION: When both AMI and UA are strictly defined, there appears to be a limited role for adding revascularization to a composite end point of death, AMI, and UA because most revascularized patients have a diagnosis of AMI or UA.

Entities:  

Mesh:

Year:  2005        PMID: 16291439     DOI: 10.1016/j.ajem.2005.04.006

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  1 in total

1.  Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials.

Authors:  Melissa C W Vaanholt; Marlies M Kok; Clemens von Birgelen; Marieke G M Weernink; Janine A van Til
Journal:  Health Expect       Date:  2018-08-14       Impact factor: 3.377

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.